Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Pyridine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 4/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | CA5A | P35218 | 1/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.31 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.31 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pyridine SCHEMBL22261990 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL1005857 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL22261964 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL1407986 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL407438 | 1.00 | NAPRT (0.60) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL25405557 | 0.97 | NAPRT (0.56) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL22151317 | 0.97 | NAPRT (0.56) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL22151316 | 0.97 | NAPRT (0.56) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL122022 | 0.97 | NAPRT (0.56) | NAPRTTSHRTDP1CA5ACA5B | |
| Pyridine SCHEMBL11617873 | 0.97 | NAPRT (0.56) | NAPRTTSHRTDP1CA5ACA5B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
| US-6617306-B2 | Therapeutic agent is conjugated to the carrier via a biodegradable disulfide bond. | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2003-09-09 | — | — | US | disclosed |
| US-20020058611-A1 | Carrier for in vivo delivery of a therapeutic agent | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2002-05-16 | — | — | US | disclosed |
| US-6258774-B1 | A POLYMER, MULTIPLE THIOL COMPOUNDS CONJUGATED TO THE POLYMER FORMING A DISULFIDE BOND, A CELL UPTAKE PROMOTER CONJUGATED TO THE POLYMER; PROTECTED FROM DEGRADATION AND RENAL CLEARANCE, IMMUNE RESPONSE IS LIMITED | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY | 2001-07-10 | — | — | US | disclosed |
| EP-1082139-A2 | CARRIER FOR $i(IN VIVO) DELIVERY OF A THERAPEUTIC AGENT | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999047173-A2 | CARRIER FOR IN VIVO DELIVERY OF A THERAPEUTIC AGENT | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 1999-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | NAPRT 98/4885TSHR 4612/4885TDP1 966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.